Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

116 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
NEDA-3 achievement in early highly active relapsing remitting multiple sclerosis patients treated with Ocrelizumab or Natalizumab.
Signoriello E, Signori A, Lus G, Romano G, Marfia GA, Landi D, Napoli F, D' Amico E, Zanghí A, Di Filippo PS, Caliendo D, Carotenuto A, Spiezia AL, Fantozzi R, Centonze D, Lucchini M, Mirabella M, Cocco E, Frau J, Maniscalco GT, Di Battista ME, Foschi M, Surcinelli A, Bonavita S, Abbadessa G, Pasquali L, Di Gregorio M, Ferrò MT, Sormani MP, Schiavetti I; ON focus study group. Signoriello E, et al. Among authors: schiavetti i. Mult Scler Relat Disord. 2024 Apr 6;87:105594. doi: 10.1016/j.msard.2024.105594. Online ahead of print. Mult Scler Relat Disord. 2024. PMID: 38718748 Free article.
Therapeutic lag: Is treatment effect delayed in progressive MS?
Montobbio N, Bovis F, Signori A, Ponzano M, Schiavetti I, Sormani MP. Montobbio N, et al. Among authors: schiavetti i. Mult Scler. 2024 Jun;30(7):843-846. doi: 10.1177/13524585241244751. Epub 2024 Apr 14. Mult Scler. 2024. PMID: 38616520
Therapeutic choices and disease activity after 2 years of treatment with cladribine: An Italian multicenter study (CladStop).
Schiavetti I, Signori A, Albanese A, Frau J, Cocco E, Lorefice L, di Lemme S, Fantozzi R, Centonze D, Landi D, Marfia G, Signoriello E, Lus G, Zecca C, Gobbi C, Iodice R, Malimpensa L, Cordioli C, Ferraro D, Ruscica F, Pasquali L, Repice A, Immovilli P, Ferrò MT, Bonavita S, Di Filippo M, Abbadessa G, Govone F, Sormani MP; CladStop study group. Schiavetti I, et al. Eur J Neurol. 2024 Jun;31(6):e16250. doi: 10.1111/ene.16250. Epub 2024 Mar 28. Eur J Neurol. 2024. PMID: 38549186
The impact of occlusive vs non-occlusive application of methyl aminolevulinate on the efficacy and tolerability of daylight photodynamic therapy for actinic keratosis.
Trave I, Salvi I, Serazzi FA, Schiavetti I, Luca L, Parodi A, Cozzani E. Trave I, et al. Among authors: schiavetti i. Photodiagnosis Photodyn Ther. 2024 Apr;46:104049. doi: 10.1016/j.pdpdt.2024.104049. Epub 2024 Mar 14. Photodiagnosis Photodyn Ther. 2024. PMID: 38490345 Free article. Clinical Trial.
Impact of COVID-19 on pregnancy and fetal outcomes in women with multiple sclerosis.
Aprea MG, Schiavetti I, Portaccio E, Ballerini C, Bonavita S, Buscarinu M, Calabrese M, Cavalla P, Cellerino M, Cordioli C, Dattola V, De Biase S, De Meo E, Fantozzi R, Gallo A, Iasevoli L, Karabudak R, Landi D, Lorefice L, Moiola L, Ragonese P, Ruscica F, Sen S, Sinisi L, Signoriello E, Toscano S, Verrengia E, Siva A, Masciulli C, Sormani MP, Amato MP. Aprea MG, et al. Among authors: schiavetti i. Mult Scler. 2024 May;30(6):707-713. doi: 10.1177/13524585241232266. Epub 2024 Mar 8. Mult Scler. 2024. PMID: 38456445
Surgical revascularization as a procedure to prevent neurological complications in children with moyamoya syndrome associated with neurofibromatosis I: a single institution case series.
Morello A, Scala M, Schiavetti I, Diana MC, Severino M, Tortora D, Piatelli G, Pavanello M. Morello A, et al. Among authors: schiavetti i. Childs Nerv Syst. 2024 Jun;40(6):1731-1741. doi: 10.1007/s00381-024-06304-z. Epub 2024 Feb 6. Childs Nerv Syst. 2024. PMID: 38316674 Free PMC article.
116 results